地诺孕素治疗子宫内膜异位症应答者与无应答者腹膜表浅病灶的组织学与免疫组化特征
前瞻性单中心单臂观察研究纳入55例子宫内膜异位症女性,地诺孕素2mg/日治疗至腹腔镜手术,按患者整体印象变化量表分为应答者36例与无应答者19例。腹膜表浅病灶的组织学形态及孕激素受体、雌激素受体、CD15表达在两组间无显著差异,不支持组织水平孕激素抵抗是地诺孕素无应答的唯一机制。
要点
- 地诺孕素应答者与无应答者的腹膜表浅病灶组织学及免疫组化无显著差异。
- 无应答者中多数病灶仍显示孕激素治疗的组织学效应,不支持单一孕激素抵抗机制。
- 深部性交痛和排便痛严重程度可能与腺体ER、PR表达相关,需扩大研究验证。
核心结论
- 腹膜表浅子宫内膜异位病灶的组织学和免疫组化特征不能区分地诺孕素临床应答者与无应答者。
- 组织水平孕激素抵抗可能不是地诺孕素临床无应答的唯一或主要机制。
研究设计与样本
- 前瞻性、单中心、单臂观察性研究,2023年1月至2024年1月纳入55例子宫内膜异位症女性。
- 所有参与者接受地诺孕素2 mg/日治疗至腹腔镜手术,病灶经组织学确诊。
- 按7点患者整体印象变化量表分为临床应答者36例和无应答者19例。
- 由同一名盲法病理学家评估病灶组织学形态及PR、ER、CD15免疫组化表达。
主要发现
- 组织学形态应答(间质萎缩且无活动性腺体)在临床应答者中29/36(80.5%)出现,在无应答者中16/19(84.2%)出现。
- 两组间PR、ER和CD15表达无统计学显著差异。
- 单因素logistic回归未发现临床应答与BMI、诊断年龄、治疗时长、组织学形态应答、腹膜病灶表型亚型、子宫腺肌症或深部内异症存在显著关联。
- 按疼痛严重程度分层的探索性分析结果与主要发现基本一致。
- 中/重度深部性交痛患者的高强度腺体ER表达比例显著低于无/轻度者,中/重度排便痛患者的腺体PR表达显著低于无/轻度者。
关键数值与推荐
- 临床应答根据7点患者整体印象变化量表自报分类。
- 疼痛严重程度按0-10分数字评定量表分为无/轻度(0-3分)和中/重度(4-10分)。
- 组织学形态应答定义为间质萎缩且无活动性腺体。
临床怎么用
- 地诺孕素治疗前无需依据腹膜表浅病灶组织学或受体表达预测临床应答。
- 对地诺孕素无应答者应超越组织水平孕激素抵抗,考虑中枢敏化等其他机制。
- 深部性交痛或排便痛严重者,可关注病灶腺体ER、PR表达与症状的潜在关联。
局限性
- 仅评估腹膜表浅病灶,未收集卵巢子宫内膜异位囊肿或深部浸润型内异症信息。
- 样本量有限,不能排除II类错误。
- 未评估孕激素受体A/B亚型及雌激素受体α/β亚型。
- 分子表达差异在盆腔痛症状发病机制中的临床相关性仍难以解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Are there histological and immunohistochemical patterns of superficial peritoneal endometriotic lesions of symptomatic patients that characterize non-response to dienogest treatment and may suggest progesterone resistance? SUMMARY ANSWER: No significant histological or immunohistochemical differences were observed in superficial peritoneal endometriotic lesions between clinical responders and non-responders to dienogest treatment. WHAT IS KNOWN ALREADY: Progestogens are effective in reducing pelvic pain symptoms in approximately two-thirds of patients with endometriosis. Treatment failure can be reasonably explained by progesterone resistance, but the available evidence is not definitive. STUDY DESIGN, SIZE, DURATION: A prospective, single-centre, single-arm, observational study was conducted between January 2023 and January 2024 in 55 women treated with dienogest, 2 mg/day, before laparoscopic surgery for endometriosis. PARTICIPANTS/MATERIALS, SETTING, METHODS: All the participants had histologically confirmed endometriosis. Patients were classified as clinical responders (n = 36) or non-responders (n = 19) based on the self-reported 7-point Patient Global Impression of Change scale. In addition, pain severity was dichotomized as either 'absent/mild' (0-3 points) or 'moderate/severe' (4-10 points) across individual pain domains, using a 0-10-point numerical rating scale. The histological morphology and the immunohistochemical expression of progesterone receptors, oestrogen receptors, and CD15 were evaluated in the excised superficial peritoneal lesions. Tissue analyses were all performed by the same blinded pathologist. MAIN RESULTS AND THE ROLE OF CHANCE: A histological morphological response to chronic progestogen treatment, defined by the presence of stromal atrophy and absence of active glands, was observed in 29/36 (80.5%) clinical responders and 16/19 (84.2%) non-responders. Furthermore, no statistically significant between-group differences were observed in progesterone receptor (PR), oestrogen receptor (ER), and CD15 expression. At univariate logistic regression analysis, no significant associations were identified between clinical response to dienogest therapy and several individual variables (i.e. body mass index, age at diagnosis, duration of therapy, histological morphological response, phenotypic subtypes of peritoneal endometriotic lesions, and presence of adenomyosis or deep endometriosis). Exploratory analyses based on pain severity categorization yielded results broadly consistent with the main findings. However, patients with moderate/severe deep dyspareunia showed a significantly lower proportion of high-intensity glandular ER expression in comparison to those with absent/mild deep dyspareunia. In addition, a significantly lower glandular PR expression was detected in patients with moderate/severe dyschezia symptoms compared with those with absent/mild dyschezia. LIMITATIONS, REASONS FOR CAUTION: Only superficial peritoneal endometriotic lesions were evaluated, and no information was collected on ovarian endometriotic cysts or deep infiltrating endometriosis. In addition, due to the limited sample size, a type II error cannot be excluded. Moreover, receptor isoforms, including progesterone receptor isoforms A and B (PR-A, PR-B) and oestrogen receptor isoforms alpha and beta (ERα, ERβ) were not assessed. However, the clinical relevance of the variance of molecular expression of progesterone and oestrogen receptors in the pathogenesis of pelvic pain symptoms remains difficult to interpret. WIDER IMPLICATIONS OF THE FINDINGS: Considering that the vast majority of lesions excised from non-responders showed clear evidence of the effect of dienogest, this study does not support the notion that intrinsic progesterone resistance may represent the sole or prominent mechanism underlying clinical non-response to dienogest treatment in women with endometriosis. However, analyses based on pain intensity dichotomization suggest that the severity of deep dyspareunia and dyschezia may be influenced by ER and PR glandular expression in superficial peritoneal endometriotic lesions. Though larger studies are warranted to further clarify these aspects, mechanisms beyond tissue-level progesterone resistance, including central sensitization, should be explored as potential contributors to symptomatic non-response to dienogest. STUDY FUNDING/COMPETING INTEREST(S): This study was partially funded by the Italian Ministry of Health, Current research IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan. N.B. and P.V. have received royalties from Wolters Kluwer for chapters on endometriosis management in the clinical decision support resource UpToDate, and both maintain a private gynaecological practice. P.V. is a member of the Editorial Board of Human Reproduction Open, the Journal of Obstetrics and Gynaecology Canada, and the International Editorial Board of Acta Obstetricia et Gynecologica Scandinavica. All other authors declare no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Berlanda N, Bandini V, Croci GA, et al. Histological and immunohistochemical characteristics of superficial peritoneal endometriotic lesions of clinical responders and non-responders to dienogest treatment. Hum Reprod. 2026. PMID: 41999626. doi:10.1093/humrep/deag059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。